Limited Stage Small Cell Lung Cancer Clinical Trial
Official title:
A Phase 2, Multicenter, Randomized, 3-Arm, Open-Label Study to Investigate the Preliminary Efficacy and Safety of the Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) Plus Tislelizumab Plus Concurrent Chemoradiotherapy in Patients With Untreated Limited-Stage Small Cell Lung Cancer
This phase 2 trial examining the combination of ociperlimab plus tislelizumab plus cCRT is expected to provide valuable data to advance treatment options in the serious unmet medical need population of LS-SCLC patients. Immunotherapy combined with chemoradiotherapy may have a synergetic anti -cancer activities. The combination of anti-TIGIT antibody and anti-PD-1/L1 antibody may augment the immune effect with tolerable safety profile. The novel therapeutic strategy with dule immune therapy in combination with CRT is expected to provide valuable data to advance treatment options in the population of LS-SCLC patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01935336 -
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
|
Phase 2 | |
| Recruiting |
NCT05443646 -
Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients
|
Phase 2 | |
| Completed |
NCT00066742 -
Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05034133 -
Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT04790253 -
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
|
N/A | |
| Recruiting |
NCT05942508 -
A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy
|
Phase 1 | |
| Completed |
NCT00019006 -
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05483543 -
Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy
|
Phase 2 | |
| Active, not recruiting |
NCT02046733 -
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
|
Phase 2 | |
| Recruiting |
NCT05623267 -
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
|
Phase 2/Phase 3 | |
| Completed |
NCT01457469 -
Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT06117774 -
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
|
Phase 3 | |
| Completed |
NCT01999881 -
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
|
N/A | |
| Not yet recruiting |
NCT05496166 -
The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT04829708 -
Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy
|
Phase 3 | |
| Completed |
NCT00470054 -
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT00084487 -
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
|
Phase 2 | |
| Recruiting |
NCT06256237 -
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
|
Phase 2 |